BioCentury
ARTICLE | Company News

KAHR, Recipharm deal

June 27, 2011 7:00 AM UTC

Recipharm's RecipharmCobra Biologics specialist biologics division and KAHR will advance KAHR-102 through preclinical and clinical testing using RecipharmCobra's maxXpress amplification service after extending a 2007 deal. The fusion protein that links portions of CTLA-4 and FasL immune-related membrane proteins is in preclinical development to treat cancer and autoimmune diseases, with Phase I testing to treat lymphatic cancer slated to begin late next year. Details were not disclosed. ...